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I. Introduction  
Mission: The Protein Structure Initiative (PSI) of U. S. National Institutes of Health (NIH) aims to obtain structural 
information on all proteins derivable from their DNA sequences (http://www.nigms.nih.gov/psi/). The objective of the 
pilot phase (PSI-1) is summarized as follows: (1) to perform pilot studies to develop high-throughput methods and 
protocols to proceed from cloning to structure determination for representatives of diverse protein-sequence families with 
no sequence similarities to proteins of known structures, (2) to identify critical areas and steps for further development to 
achieve a high-throughput operation, and (3) to obtain the metrics for assessing the magnitude and scale required for the 
production phase of PSI (PSI-2) to achieve the overall PSI objective of a comprehensive coverage of the protein structure 
space. 
Objective: In the pilot phase, the Berkeley Structural Genomics Center (BSGC) set the goal of obtaining structural 
information of a near complete set of all soluble proteins in two related minimal organisms (the pathogens, Mycoplasma 
pneumoniae (MP) and M. genitalium (MG), with ~700 and ~500 genes, respectively).   
Pipeline:  To achieve our mission, we have developed methods and protocols to automate or parallelize many processes 
from cloning the target genes to structure determination.   Over all pipeline schemes for the single-path approach used in 
the initial two year period and the multiple-path approach used for the rest of the PSI-1 period are shown in Fig. I.1. 
 
    
Fig. 1. Single-Path Approach vs. Multi-Path Approach for soluble proteins. A large number of target genes and 
their homologs were selected (see Target Selection below), and the majority of them could be cloned. Of these, 
some were over-expressed as proteins in soluble form, as protein aggregates, or as insoluble inclusion bodies. 
In the single-path mode, only the soluble proteins were screened for crystallization or NMR studies, and of 
these, only some yielded structures. The overall success rate for the single-path approach was about 5%.  By 
contrast, in the multi-path mode, those clones not expressing, or under-expressing could be re-cloned with 
different constructs and/or into different vectors to obtain additional over-expressing clones; proteins that 
aggregate or could not be concentrated underwent Optimum Solubility Screening (see below) to find optimum 
conditions in which they were soluble and homogeneous.  Those proteins that were insoluble underwent an On-
column Refolding process (see below). Proteins that were chemically and conformationally homogeneous were 
used for NMR or crystallization studies. BSGC experience shows that for this multi-path approach the overall 
success rate increased to about 16%.  *Processes which are automated or semi-automated. 
 
 
II.  Metrics and Lessons Learned  
 Based on BSGC’s results during the PSI-1 period, we learned the metrics and lessons required for a structural 
genomics approach for a large scale structure determination effort, some were predicted and others were unexpected and 
surprising.  Although some details may be different from those of other PSI-1 centers, the general conclusions of metrics 
and lessons are expected to be valid.   They are summarized below: 
1. The steps required to proceed from cloning a gene encoding a protein to determining its 3D structure can be divided 
into two distinct categories: (1) those where the underlying science and technologies are well understood, thus, 
automatable by instrumentation or programming, and (2) those where the underlying science is only partially known and 
the outcome of the processes are unpredictable. The most practical approach for steps of the second category is multi-
variable screenings.  
2. The single-path (low-hanging fruit) approach (Fig. I.1), whereby, for a large number of diverse genes, one single optimized 
path is taken from cloning to structure determination, has less than a 5% success rate on average in discovering 
structures of “unique” proteins, the proteins without sequence homology to those of known structures in the Protein 
Data Bank (PDB) (Berman et al., 2000).  
3. The multi-path approach (Fig. I.1), where feedback loops and multi-factor screenings are employed for one or more critical 
steps in the path for challenging proteins that fail by a single-path approach, has a 16% or higher success rate for 
discovering the structure of unique proteins.  
4. Approximately half of the structures of unique proteins revealed a new fold, and the remaining half are “remote 
homologs” (similar structure without sequence similarity) of known folds. 
5. Approximately 2/3 of the structures of “hypothetical proteins” (proteins that have no sequence homologs among the 
proteins of known function) infer one or a few possible molecular functions that could be experimentally tested. 
6. The protein fold space can be mapped in three-dimensional space based on pair-wise structural similarities (Hou et al., 
2003, 2004), thus, providing a platform for representing all protein structures, "the protein structure universe".   
 
 
III.  Selection of Target Proteins for High Throughput Structural Characterization 
 
 
Method:  A structural genomics target is a protein that is selected to determine its 3-D structure.  BSGC targets during the 
PSI-1 period include Mycoplasma proteins as well as their sequence homologs from other prokaryotes.  In general, all rounds 
of target selection involved three common steps.  Since almost all MG genes have their homologs in MP, we started each 
step with the set of 677 MP ORFs described in the original annotation of the genome (Himmelreich et al., 1996).  Each ORF 
was then augmented with a family of homologs from available, fully sequenced prokaryotic genomes to make a target set.  
First, all target sets recognizably homologous to proteins of known structure were removed from further consideration.  
Next, target sets of proteins that were predicted to be unsuitable for high-throughput study (e.g., those with predicted 
transmembrane helices) were eliminated.  Finally, specific targets were chosen from among proteins in the remaining target 
sets.  The number of targets chosen per family, or parallelism, varied amongst selection rounds.  A flow diagram of target 
selection for a sample round is shown in Fig. 2.  
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Fig. 2. Target selection scheme for Mycoplasma genes used at BSGC. 
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“on hold,” and sequences from TargetDB (Chen et al., 2004), for which a structure has been solved by another 
structural genomics center.  We also included sequences of BSGC targets that have progressed to the “Traceable 
Map” stage, as this usually indicates the structure will soon be completed.  The database was updated prior to each 
target selection round.   
3. snr:  the non-redundant set of protein sequences from Swiss-Prot (Boechmann et al., 2003).  We included all 
sequences in the swissprot, trembl, and trembl_new files (downloaded 30 July 2001 for round 2, 30 November 2001 
for round 3, 21 October 2002 for rounds 4-5 and 7-8, and 26 February 2004 for round 6) from Swiss-Prot, which 
had been filtered with the SEG (Wootton, 1994) and PFILT (Jones and Swindells, 2002) programs using default 
options.  The filtering was done to reduce the chance of profile corruption (Schaffer et al., 2001), which can lead to 
inaccurate results. 
4. Available genomes:  NCBI database of proteins from sequenced bacterial and archaeal genomes 
(ftp://ftp.ncbi.nih.gov/genomes/Bacteria).  Targets were only chosen from genomes for which the BSGC had 
access to purified genomic DNA.  These species are listed on the BSGC website (http://www.strgen.org). 
Identification of known structures: At the beginning of each round of target selection, all MP proteins and their 
homologs were considered potential targets.  These were then removed from consideration if they were detectably 
homologous to other proteins of known structure. 
1. In each automated target selection round, sequences of all MP ORFs were compared to the knownstr database using 
several sequence comparison tools such as PSI-BLAST (Altschul et al., 1997). PSI-BLAST position-specific scoring 
matrices (PSSMs) were constructed for each MP ORF using 10 rounds of searching our “snr” database with a matrix 
inclusion threshold E-value of 10-2 in most rounds. 
2. The PSSMs were used to search the knownstr database, and any hits with an E-value of 10-1 or below were 
eliminated from consideration as targets.  This significance threshold was chosen to increase the likelihood of 
detecting more remote homologs, even though it had some risk of false positives being removed from the target 
list.   
3. After the second round for target selection, the matrix inclusion threshold was increased in order to increase the 
possibility of identifying remote homologs, at the risk of a higher rate of corrupted PSSMs. 
 
4. Because of the latter possibility, we also used BLAST (Altschul et al., 1990) and Pfam (Bateman et al., 2004) in target 
selection rounds 3-6.  All MP ORFs with a BLAST hit against knownstr with an E-value of 10-1 or below were 
eliminated from consideration as targets, in addition to those already eliminated by PSI-BLAST. 
5. Pfam was also used to detect known structures.  The HMMER tool (Eddy, 1998) was used to compare the Pfam_ls 
library of hidden Markov models to both the knownstr database and the database of MP ORFs, using the family-
specific “trusted cutoff” score as a cutoff for assigning significance.  We eliminated from consideration all ORFs that 
had a significant hit to a Pfam family that had also matched at least one known structure.  
Identifying MP targets predicted to be less tractable for high-throughput study: 
 
1. As the next step in each target selection round, we eliminated MP proteins and domains that were likely to be 
predictably less tractable for high-throughput study.  These included proteins with regions of amino acids predicted 
to be in transmembrane segments, coiled coils, and regions of low complexity.  The predictions were made by the 
SEG program  (version dated 24 May 2000) for proteins with low complexity regions spanning more than 20% of 
the protein lengths, the CCP program (written by J Kuzio at NCBI, version dated 14 June 1998), using the algorithm 
of Lupas (Lupas, 1996), for proteins with coiled coil regions, and two programs to identify transmembrane regions, 
TMHMM 2.0a (Krogh et al., 2001) and  PHDhtm (Rost et al., 1995) version 2.1 (October 1998).  Any transmembrane 
region predicted by either program eliminated an MP ORF from consideration as a target in rounds 2-5.  
2. We also eliminated potential targets that were long and therefore likely to be challenging; in earlier rounds (round 1-
2) of target selection, the length cutoff was 400 amino acids, and in later rounds (round 3-8) it was increased to 700 
amino acids.  
3. Finally, we excluded proteins annotated as ribosomal components, as these were expected to be unlikely to be stable 
in the absence of binding partners. 
Identifying homologues of MP proteins as targets: In addition to the MP proteins themselves, homologous proteins 
from other prokaryotes were also chosen as targets.  Each MP protein (or predicted domain in round 6) that passed 
through the above filters was used to search the database of available genomes using PSI-BLAST.  PSI-BLAST PSSMs were 
constructed for each MPe ORF using 10 rounds of searching the nonredundant sequence database “snr” (as described 
above) with default parameters; the PSSMs were then used to search the database of genomes.  BLAST version 2.2.4 was 
 
also used (with default parameters) in rounds 4-8 to search the genome database.  All proteins identified by BLAST 
or PSI-BLAST with E-values more significant than 10-4, with the region of local similarity covering at least 50 
residues, were considered as possible targets.   
 
Other factors considered: Potential targets from MP were always selected if they passed an additional screen to 
ensure they could be expressed in the Escherichia coli expression system used at the BSGC.  MP and other related mollicutes 
such as Ureaplasma urealyticum  can use UGA codons to encode the amino acid tryptophan, whereas UGA is a stop codon in E. 
coli.  Thus, cloned MP proteins with this codon would express truncated proteins in E. coli.  In cases where a UGA codon was 
within about 30 bases of either end of the gene, it could easily be mutated to a UGG codon during cloning, using mutating 
PCR primers.  Other UGA codons, called internal UGA codons, could only be mutated in a more difficult multi-step cloning 
procedure.   
 When there were too many homologous targets, high priority was given to targets from thermophiles and 
halophiles, as these were expected to be experimentally more tractable, for example being partially purified by heating 
the E. coli lysate.  
Target De-selection:  The BSGC only seeks to solve structures for protein domains for which the structure cannot be 
reliably predicted via bioinformatic methods.   We therefore de-select and stop work on targets whose structures of 
similar proteins have been solved by other groups.  Most deselection analysis steps are automated.  However, the final 
decision on whether to stop work on a target is performed manually, to decrease work lost due to potential false 
positives.  This automated analysis and manual review are both performed weekly.  More details of the rationale 
behind this two step approach are given elsewhere (Chandonia et al., 2006). 
 
IV.  Protein Production 
 For our purpose, E. coli recombinant expression systems are the best option in terms of economy and ease of 
protein production.  Prokaryotic cell-free protein synthesis has also been used occasionally.   
Cloning:  For the past two years, BSGC has used an in-house version of the Ligation Independent Cloning (LIC) 
methodology (Aslanidis & de Jong, 1990). This LIC system provides both efficient high-throughput cloning and flexibility in 
 
fusion construction. The LIC method relies on common linker sequences to anneal and join the target segments to the 
vector. A Tobacco Etch Virus (TEV) cleavage site allows cleavage of the fusion tag. The fusions (MBP, GST, TRX, NusA) 
are utilized primarily for enhancing soluble expression. In addition to the N-terminal His6 tag, we have a PCR-based method 
of preparing targets containing a C-terminal His6 tag that can be used in cases where the N-terminal His6 tag is ineffective. 
The simplicity of the present LIC cloning scheme allows for most of the experimental steps to be performed robotically in 
groups of 96 targets. The following steps are currently automated on the Biomek 2000 (Beckman Coulter, Inc., Fullerton, 
CA) robot: PCR reaction setup and cleanup, PCR product analysis by E-gel 96 (Invitrogen, Inc., Carlsbad, CA), LIC reaction 
and transformation, Mini-expression setup, Clone preservation in agar stab, and Plasmid preparation.  
Small-Scale Expression: After transformation into the expression host, two colonies are selected and grown in an auto-
inducing medium (Grabski et al., 2003). Cells are grown in a 96 deep-well plate overnight, spun down, resuspended, and 
sonicated using the Misonix 3000 sonicator (Misonix, Farmingdale, NY). The lysate is spun, and both soluble and insoluble 
fractions are run on SDS/PAGE. Presently, all steps, from PCR reaction for 96 targets to analysis of level of expression of 
the targets, are automated and can be achieved in 5 days (Nguyen et al., 2004). 
Large-Scale Preparation of Cell Paste:  Previously we had used Luria broth with isopropyl-β-D-1-thiogalactopyranoside 
(IPTG) induction. This required the manual addition of IPTG. For the last 2 years we have used an auto-inducing medium 
(developed by Dr. William Studier from Brookhaven National Lab) that induces expression by balancing the levels of 
glucose and lactose as carbon sources. This formulation spontaneously induces high levels of target protein without the need 
to monitor growth and increases the soluble expression of target proteins. Two types of auto-inducing media are used: 1. 
ZYP: native medium, 2. PASM: medium for labeling the target protein with Seleno-methionine. 
Protein Purification:  Parallel purification is performed on three AKTA Explorer work stations (GE Healthcare, 
Piscataway, NJ). We have recently changed our protocol to the following: 5 targets are sequentially purified through three 
columns in an automated way using the AKTA Explorer with 3D Kit (software necessary for programming these steps). 
The three columns being used are: HisTrap metal-chelating—Desalting column—HiTrap Q/S HP 5 ml column (GE 
Healthcare, Piscataway, NJ). This method takes 10 hr to complete.   
Quality Control Assessments: 
 
All purified proteins undergo quality control steps 1–5 as listed in Table 1. 1-D NMR is performed on proteins smaller than 
45 kDa that did not crystallize.   
Table 1. Protein Characterization. 
Parameters Method 
1.  Purity SDS/PAGE stained with Coomassie Brilliant Blue R 
2.  Monodispersity Dynamic light scattering (DynaPro 99, Wyatt Technology Corp., Santa Barbara, CA) 
3. Aggregation state Native gel (Phast system, GE Healthcare, Piscataway, NJ) 
Analytical size exclusion chromatography (G4000SWxl, Tosohaas Corp., 
Montgomeryville, PA) 
4.  Molecular weight Mass spectrometry (MALDI-TOF, Voyager DE, Applied Biosystems, Foster City, 
CA) 
5.  Bound elements ICP-MS (University of Georgia, Athens, Ga) 
6.  Functionality Panel of enzymatic assays (In collaboration with Dr. A. Yakunin, University of 
Toronto, Toronto, Canada) 
7.  1-D NMR Bruker DRX 500 NMR spectrometer using an 11 (one-one) pulse sequence  (Dr. D. 
Wemmer, University of California, Berkeley, CA) 
 
Protein production summary:  As mentioned in the Introduction, BSGC is unique in that we have chosen as our target 
two minimal organisms (MP and MG) with the smallest genome size. Our targets have no sequence homology to those of 
known structures.  Even with a small starting pools of targets, a multi-path approach eventually allowed us to produce most 
of our targets. For the minimal organism MP with 677 full-length predicted proteins, after filtering out the proteins that are 
structural homologs of known structures, those containing transmembrane domains, coiled coils, low complexity regions, 
and multiple UGA codons, there remained 82 full-length target genes. Up to 10 homologs for each gene from other 
organisms were added to make a total of 386 targets.   Out of 386 targets, 318 were successfully cloned and 261 clones gave 
good expression.  From those, 191 proteins were purified in good quality and amounts suitable for crystallization screening.  
 
  
V. Technical Development for Challenging Proteins  
Heat Shock and High Salt Growth: Over-expression of many heterologous proteins results in production of refractive 
bodies, also known as inclusion bodies (IB). The level of these insoluble proteins can sometimes be reduced by lowering the 
growth temperature upon induction; changing the media composition; expressing the protein as a fusion with MBP, GST, 
thioredoxin, or NusA (Sachdev and Chirgwin, 1998; Harrison, 2000); and inducing the expression of chaperones. Other 
approaches for reducing IB production are salt and heat-stress which induce complementing defense mechanisms in 
bacterial cells, including intracellular accumulation of osmolytes or synthesis of heat-shock proteins, respectively (Kempf 
and Bremer, 1998; Bukau and Horwich, 1998). Simple heat shock before induction is known to enhance the solubility of 
some recombinant proteins produced in E. coli (Chen et al., 2002).  Some osmolytes behave as “chemical chaperones” by 
promoting the correct folding of unfolded proteins in vitro and in the cell (Samuel et al., 2000; Yang et al., 1999; Voziyan and 
Fisher, 2000; Diamant et al., 2001). We have combined these two elements, heat shock and high salt media, to increase the 
fraction of soluble protein produced from targets. 
 We have tested a protocol that combines heat shock and high salt growth (Oganesyan et al., 2006).  The cells were 
grown in the presence of 0.5 M NaCl and incubated at 47oC at the beginning of induction with IPTG for 20 minutes. The 
temperature was then decreased to 20oC for overnight growth. These cells expressed only soluble target, although the total 
level of expression was 10 fold lower than when grown under “normal” conditions. This soluble sample was crystallized, 
and its structure was solved (Das et al., 2004).  
On-Column Refolding:  Inclusion body formation, as mentioned above, can be minimized or avoided by applying 
complex efforts to enhance production of soluble protein. On the other hand, protein production from inclusion bodies has 
a number of merits. They are: (1) produced in high yields, even those that are toxic for bacterial cells; (2) generally protected 
from proteolytic degradation; (3) and easily purified and solubilized. The main challenge is to convert inclusion bodies to 
properly folded, biologically active proteins.   We have developed an on-column chemical refolding method (Oganesyan et 
al., 2004), for insoluble His-tagged proteins expressed in E. coli, partly based on the method described by Rozema and 
Gellman (1996).  IBs solubilized in urea are first bound to a metal-chelating affinity column and exposed to a detergent wash 
to prevent misfolding. This is followed by a β-cyclodextrin wash that removes the detergent and promotes correct folding 
 
(Daugherty et al., 1998). The target protein is eluted with Imidazole, and then goes through further purification steps—IEX 
and/or SEC—before evaluation by Dynamic Light Scattering (DLS). As an example, ten of the PSI-1 targets from BSGC 
that expressed insoluble protein were purified using this method. Three of the ten targets could not be refolded, but we 
obtained 30–100% refolding from the other seven. All refolded proteins were subjected to DLS analysis, and five out of 
seven refolded proteins were monodisperse. Six of the seven refolded proteins were able to produce crystals of varying 
qualities.  
Optimum Solubility (OS) Screen:  For structural studies, the first step after a protein is purified is to concentrate it in its 
purification buffer to a concentration suitable for crystallization or NMR studies. In about 25% of the cases, this step fails 
because the protein aggregates and precipitates; this adverse phenomenon is totally unpredictable. Inspired by a screen for 
NMR studies (LePre & Moore, 1999), we have developed a screening method (Jancarik et al., 2004) in which we test a panel 
of buffers and many additives to obtain the most homogeneous and monodisperse solution for each protein that usually 
aggregates and cannot be concentrated prior to setting up crystallization screens.   
 A panel of 24 buffers is tested using the hanging-drop method and vapor diffusion equilibrium. After monitoring 
precipitation, the conditions leading to clear drops are selected for DLS characterization. For this part of the screen, only 24 
µl of protein (with concentration ranging from 3 mg/ml to 10 mg/ml) are required. If the DLS results are not optimal, a 
series of additives are tested in the presence of the best buffer selected from the initial screen, and again DLS is used to 
determine the best condition.  The OS screen has been performed on 14 samples of cytoplasmic proteins that had ag-
gregated as measured by DLS and had precipitated upon concentration or could not be concentrated. The OS screen 
indicated that out of the 14 protein samples, the DLS of 11 of them could be improved in different buffers, and, in some 
cases, an additive further improved DLS.  Nine of these proteins could subsequently be crystallized.   
 
VI. Structure Determination 
  The overall flow of the process for determining three-dimensional (3D) structures of proteins is well 
established. Although much of the science involved is understood, and many of the key techniques are well developed, the 
underlying science is not well understood in some steps, and so the outcome appears almost stochastic and unpredictable. 
Thus from an engineering and automation point of view, the component steps in the process from purified protein to 3D 
 
structure can be divided into two categories: (1) the steps that are automatable and can be operated in a high-throughput 
mode, and (2) the steps that can only be processed in a multi-path approach by screening a large number of conditions, 
factors, and paths to increase the probability of success for such steps.   The success rate for the single-path approach from 
purified protein to unique structure is, on average, about 9%. In the PSI-1 pilot stage, despite the limited manual multi-path 
approach, we have been able to increase the success rate to ~27% (the corresponding success rate for clone to structure is 
about 5% and 16%, respectively) with additional multi-path steps and automation. The overall pipeline at BSGC is 
schematically shown below. 
   
 
Fig. 3. Multi-path flow diagram for the process from pure proteins to 3D structures.  The process for each step is in 
parenthesis. The automated steps are marked by **; steps that are partially automated or steps for which screens have been 
developed but haven’t been automated are marked by *.   
Crystallization:  The science of protein crystallization is not well understood.  Currently, the most successful and practical 
method for finding protein crystallization conditions is to screen a large number of conditions through our sparse matrix 
crystallization screening method (Jancarik & Kim, 1991) and its commercially available variations (e.g., from Hampton 
Research, Aliso Viejo, CA).  During this process, we use the Hydra Plus One (Matrix Technologies Corp., Hudson, NH) 
and the Phoenix Liquid Handling System (Art Robbins Instruments, Sunnyvale, CA) crystallization robots with 96 well 
plates.  We routinely screen 4 x 96 crystallization conditions at two temperatures. Once one or more promising crystal hits 
are found, we optimize the hit conditions using a protocol we have developed to fine-tune the conditions to obtain good 
diffraction quality crystals.  As a result of the on-column refolding step and the optimum solubility screen described earlier, 
our success rate for the purified-protein-to-diffraction-quality-crystal process is about 27%.  
Diffraction Data Collection: Many of the steps in diffraction data collection at Berkeley Lab’s Advanced Light Source are 
hardware and software assisted. They include the robotized automatic mounting of frozen crystals, point-and-click crystal 
centering, and the capability to screen frozen crystals to search for well-diffracting crystals.  
Structure Solution: Once experimental data are collected, high-throughput methods are applied to solve and complete a 
structure. We routinely use software developed for structural genomics efforts, such as HySS for substructure determination 
(Grosse-Kunstleve & Adams, 2003). This software is part of the PHENIX package. The high level of automation HySS 
provides makes it possible to determine a substructure at the beamline immediately after data have been collected and 
processed. Once the anomalous substructure has been located, phase calculation and substructure refinement are 
performed, using SOLVE (Terwilliger and Berendzen, 1999), MLPHARE (CCP4, 1994), or CNS (Brunger et al., 1998) as 
dictated by data quality. In more challenging cases the SHARP (de La Fortelle and Bricogne, 1997) program is used.  The 
pipeline is shown below. 
 
  
Fig. 4. Flowchart for structure solution, model building, and structure completion used by BSGC in the PSI pilot phase. 
 The results of phasing are continued into phase improvement by density modification, using CNS (Brunger et al., 
1998), DM (Cowtan, 1999), and RESOLVE (Terwilliger, 2000; Terwilliger, 2002). Visual inspection of the electron density 
map is used to determine whether more experimental data should be collected. For model building we use automatic 
software when possible. If data extend to 2.2 Å, the ARP/warp (Perrakis, Morris & Lamzin, 1999) suite is used, and in a 
favorable case 90% of the model is built. With lower resolution data (between 3 and 2.2 Å) the RESOLVE software is used 
to build an initial model, typically at least 50% of the main chain is built. The model is then used as a basis for manual model 
completion. In cases of poor data quality or resolutions below 3.0 A, a manual model building is used. Structure refinement 
and model completion makes use of the standard refinement tools: CNS and REFMAC (Murshudov, Vagin & Dodson, 
1997), automated water assignment, and manual rebuilding if necessary.  
 
VII. Summary of BSGC Throughput during the PSI-1 Pilot Phase  
 For the minimal organism MP with 677 full-length predicted proteins, after filtering out the proteins that are 
structural homologs of known structures, those containing transmembrane domains, coiled coils, low complexity regions, 
and multiple UGA codons, there remained 82 full-length target genes.  Up to 10 homologs for each gene from other 
organisms were added to make a total of 386 targets.  Of those, 318 were successfully cloned (not counting clones of 
domains of full length proteins).  Our overall success rates are shown in Table 2. 
Table 2. BSGC success rate for full length target proteins during the PSI-1 pilot phase. 
Full length genes cloned Soluble expression Purified proteins Crystallized Structures solved 
318 261 191 104 93 
 
BSGC Solved Structures: Almost all of BSGC targets are “unique” in that the majority of the targets have no sequence 
homologs among proteins of known structures. Thus we have had a high rate of discovering many new protein folds.   A 
number of these also revealed unexpected bound ligands suggesting their possible biochemical functions, and others have 
unusual oligomeric structures not predicted by genetic or biochemical methods.  Thus, the majority of BSGC structures 
belong to one of four categories: (1) hypothetical proteins with novel folds, (2) proteins with novel folds that suggest their 
molecular functions, (3) proteins with “unique” sequences that reveal novel folds, and (4) hypothetical proteins with known 
folds (“remote homologs”).  The protein structures in categories 2 and 4 can infer possible molecular functions (Kim et al, 
2004).  
 
IX. Structural proteome of a minimal organism  
When the genomic sequence of the first organism was completed, development of computational methods to analyze the 
sequenced genes became the key for extracting valuable new information, most of which was totally unpredicted and 
unexpected. The critical importance of the computational methods became even more evident as more genomic sequences 
became available. As was the case with sequence genomics, the development of computational methods for analysis of the 
3D structures of proteins is going to be the key to mining valuable information from the 3D structures of proteins obtained 
 
from PSI and other sources. Toward this objective, we have developed a computational process to represent all unique 
protein structures in a multidimensional space based on structural similarities and in 3-D space for approximate visual 
representation of the multidimensional structural space. 
The Protein Structure Space Mapping:  The PSI objective of near-complete coverage of protein structure space needs a 
representation method of the space. It has been shown recently (Hou et al., 2003, 2004) that the protein structure space can 
be “mapped” in three-dimensions, in which all the known and newly determined protein structures are distributed in a 
highly organized way.  Furthermore, the demographic distribution of the protein structures in the map is understandable 
from the viewpoints of protein architectural features and protein fold evolution. Thus, this representation of the protein 
structure space provides a unified platform on which all the protein structures of the PSI, as well as others, can be mapped, and 
various structural information, functional information, and evolutionary information can be mapped and mined 
computationally, once such computational tools are developed.  
Mapping of the Protein Structure Space:  One of the major objectives of PSI is to obtain a broad coverage of the protein 
structure space. To conceptualize the space, and derive new information from the demographic distribution of protein 
structures in the space, it is useful to define it. Calculating all pair-wise structural similarity for all non-redundant protein 
structures (~ 2000) in PDB, and converting them to structural dissimilarity scores, we were able to map the protein structure 
space in three-dimensional space. To accomplish this, we used the mathematical method known as multidimensional scaling 
(Hou et al., 2003, 2004). In the structural space, each point represents a unique protein structure family.  In this space, each 
point is located in the space that best fits all pair-wise distances between the point and all the rest.   Two points are close to 
each other when their structures are similar. The following observations were made: 
1. The protein structure space is sparsely populated, and all protein structures are confined to four elongated regions, each 
characterized by particular architectural features of proteins. This observation strongly suggests that evolution of 
proteins may have been strongly restricted by the requirement of architectural stability of proteins. 
2. Short and poorly structured proteins are mapped near the “origin,” and the size of proteins and the extent of secondary 
structure, or super-secondary structure, elements generally increase along each feature axis as indicated in Fig. V.6. This 
suggests that these trends may be related to protein-fold evolution.  
 
3. The three feature axes and the three coordinate axes provide a completely general and objective way of describing and 
classifying protein structures, thus providing a new demographic addressing a system similar to library cataloguing. 
Furthermore, these structure features are easily computed from protein structure information without solving any 
structural alignment optimization algorithms, so they may serve as basic feature vectors for a fast, generalized, and 
automatic protein structure classifier.  
4. All new structures from the PSI program and others map approximately within the “envelope” defined by the structural 
space originally found using ~2000 non-redundant structures of PDB, suggesting that the “protein structure universe” is 
finite.  
This type of representation of protein structure space provides a unified platform on which one can map all the PSI 
structures and others, in order to globally visualize the structural relationship among them, to identify the regions of 
different structural population densities for suggesting additional new structures needed, and to infer possible protein-fold 
evolution. Furthermore, all biochemical and biophysical functions can be mapped on the space to obtain a global view of 
the molecular function-structure classification and fold/function relationship on a global level. 
 
 
Fig. 5 Global representation of protein fold space. All together, 1898 unique protein structure families are 
represented by spheres in the three-dimensional space. α, β and α/β class structures follow three elongated 
directions denoted by α, β and α/β feature axes (Hou et al., 2004).  Class designation for each structure family 
according to the SCOP (Murzin et al., 1995) database is indicated by red for α-class, yellow for β-class, blue 
for α+β class, cyan for α/β class, pink for membrane proteins, and black for multidomain proteins.  In most 
cases, SCOP classification approximately agrees with the demographics of the protein fold space.  Some 
sample structures are shown. 
Structural families found in the minimal organism, MP:  The unique structural families represented by all the soluble 
MG/MP proteins and their homologs are mapped on the protein structure universe.  As expected they are located within 
the envelope defined earlier by the 1898 non-redundant structures of PDB.  There appears to be a paucity in β-class 
proteins in these minimal organisms. 
 
Fig.6.  Protein structure families determined at BSGC (red) mapped on the protein structure universe.  Most of the BSGC 
structures had no sequence homologues in PDB structure database.  About one half of them had new folds and occupy 
empty spaces in the protein structure universe, and the other half turned out to be "remote homologues" of structures of 
known folds and occupy the same or very close to pre-occupied locations. 
Structural coverage of a minimal oganism, MG:  At the start of PSI-1, about 2/3 of the MG proteins had no structural 
information, of which the majority (about 43% of total) were predicted to be soluble proteins (see Fig. 6a).  At the end of 
 
PSI-1, we now have structural information for over 90% of the soluble proteins of this minimal organism (Fig. 6b) 
(Chandonia and Kim, 2006).   
 
Fig. 7 (Left) At the start of PSI-1, 3-D fold information was available for 34% of the proteins in Mycoplasma genitalim, the rest 
of the proteins belonged to membrane proteins (13%), low complexity proteins (10%) and soluble proteins of unknown 3-D 
folds (43%).  (Right) By the end of PSI-1, 3-D fold information was available for over 90% of soluble proteins in this 
minimal organism.   
Further analysis of this and other structural proteomes of small prokaryotes reveals an interesting conservation pattern for 
protein fold for proteins of particular functional categories, details of which were described recently (Chandonia and Kim, 
2006). 
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